Oncology deals with the diagnosis and treatment of cancer. It is one of the most dynamic segments moving at a rapid pace in terms of research and development activities, diagnostics, and treatment. Oncology encompassed several diseases (or indications). Oncology Based Indications are further classified as Blood cancer, Solid tumors, and Lymphomas.
Over the past few decades, the overall incidence and prevalence of cancer have grown significantly. According to International Agency for Research on Cancer (IARC), in 2018 there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. In the coming years, the global burden of cancer disease is likely to increase due to various risk factors. The risk factors include an increase in tobacco and alcohol consumption, smoking, obesity, age, unhealthy diet, immunosuppression, physical inactivity, exposure to Cancer-Causing Substances, and many others. Similarly, the cancer is diagnosed based on Tumor Biomarker Test, Imaging, Biopsy, Liquid Biopsy, Immunohistochemistry, In Situ Hybridization, and others. Significant advancement has been made in cancer diagnostics approaches. Similarly, in treatment as well which has improved the quality of life of the affected person. However, late diagnosis is still one of the major challenges which hamper the treatment. The treatment approaches adopted by the physician depending upon various factors.
DelveInsight offers 100+ Oncology Based Indications reports such as Lung Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Gastric Cancer, Kidney Cancer, Brain Cancer, Thyroid Cancer, Skin Cancer, Bladder Cancer, Cervical Cancer, Blood.
The reports are classified namely as market reports, epidemiology reports, drug insights reports, and diagnostics reports. The reports cover various important aspects associated with the respective domain. It assists companies to understand the market dynamics, trends, major developments and also prove opportunities to strategically positioned their product in the market.
Key highlights of the Oncology Based Reports offered by DelveInsight –
- Market Report
The market report covers the epidemiology as well as the market trends in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Moreover, it provides an overview of the treatment practices, emerging drugs, market share of the individual therapies, market drivers, market barriers, key companies in the domain, and unmet medical needs that will help to understand the underlying potential of the market and the opportunities.
- Drugs/Pipeline Report
The Drug/Pipeline Insight report provides comprehensive insights about the companies and pipeline therapies in the therapeutics landscape. It covers the drug profiles, including clinical and non-clinical stage products, product type, stage, route of administration, and molecule type as well as the inactive pipeline products in the therapeutics space.
- Epidemiology Report
The Epidemiology Forecast Report covers the in-depth analysis of the disease, historical and forecasted epidemiology in the 7MM as well as the patient segmentation, disease risk & burden, and the factors driving growth in a specific patient population.
- Diagnostics Report
DelveInsight’s Oncology Based Diagnostics Report delivers an in-depth understanding of the historical and forecasted market trends for the diagnostic device. It provides an overview of diagnostics devices, applications, market share, market drivers, market barriers, unmet needs, key companies operating in the market and their pipeline products as well as PEST Analysis.
The global market size of the cancer therapy market is expected to increase significantly in the coming years with the active involvement of the major pharmaceutical companies in the therapeutics segment. Currently, some of the key companies in the Oncology market include Roche, Novartis, Celgene, Bristol Myers Squibb, Johnson & Johnson, Merck, Pfizer, AstraZeneca, BeiGene, Incyte Corp, Gilead Sciences, Takeda, Sanofi, Amgen, Daiichi Sankyo, Astellas Pharma, 3SBio, Eli Lilly and Company, AbbVie, and several others. Some of the companies are focussing on a single Oncology Indication while some are exploring multiple indications. Owing to various factors the burden of cancer is likely to increase in the coming years. To provide an effective therapeutics solution the oncology segment will witness the entry of globel pharma companies in the diagnostics and therapeutics segment. Overall, the extensive research and development activities, rise in investment, entry of novel therapies, advancement in cell therapy, and improvement in diagnostics approaches are expected to provide effective results in the prevention and treatment of cancer in the coming years.